We are thrilled to announce a pivotal milestone for Biologics. As of today, we’ve gained access to our first gene therapy, Casgevy. CASGEVY is a one-time gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive crises (VOCs) live severe VOC-free.
Read the full press release here: InspiroGene by McKesson Partners with Vertex to Expand Distribution Options for CASGEVY® (exagamglogene autotemcel)